COVID-19 Infection in Multiple Sclerosis Patients Treated with Rituximab Compared to Natalizumab and...
COVID-19 Infection in Multiple Sclerosis Patients Treated with Rituximab Compared to Natalizumab and Healthy Controls: A Real-World Multicenter Study
About this item
Full title
Author / Creator
Mathew, Thomas , Garg, Surabhi , John, Saji K. , Kimi, Mal S. , Chhakchhuak, Naom Z. , Koshy, Sherina , Yangdonq, Tenzin , George, Molly , Bhardwaj, Shagun , Reddy, Yerasu M. , Murgod, Uday , Kamath, Vikram , Shivde, Sonia , Badachi, Sagar , Huddar, Akshata , Sarma, Gosala R. K. and Nadig, Raghunandan
Publisher
India: Medknow Publications & Media Pvt. Ltd
Journal title
Language
English
Formats
Publication information
Publisher
India: Medknow Publications & Media Pvt. Ltd
Subjects
More information
Scope and Contents
Contents
The impact of coronavirus disease 2019 (COVID-19) infection on patients with multiple sclerosis (MS) undergoing various immunomodulating therapies can vary. Individuals on B-cell therapy, such as rituximab, may be more susceptible to infection compared to those treated with natalizumab.
The objective of this study was to determine the incidence...
Alternative Titles
Full title
COVID-19 Infection in Multiple Sclerosis Patients Treated with Rituximab Compared to Natalizumab and Healthy Controls: A Real-World Multicenter Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c141ed01b5974703bfa608c9a7dc78c3
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c141ed01b5974703bfa608c9a7dc78c3
Other Identifiers
ISSN
0972-2327
E-ISSN
1998-3549
DOI
10.4103/aian.aian_151_24
